Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
The AAV9-miR-21 and AAV9-NC vectors were obtained from Syngen Tech Company (Beijing, China). The vectors were delivered to the myocardium via tail vein injections (total dose of 5 × 1012 vg/200 μL per mouse).
Copyright and License information: ©2021 Li, Meng, Han, Yang, Wang, Zhu, Cui, Zuo, Xu and Chang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
